The purpose of the study is to identify doses and schedules of VOB560 and MIK665 that can be safely given and to learn if the combination can have possible benefits for patients with Non-Hodgkin lymphoma (NHL), Multiple Myeloma (MM) or Acute Myeloid Leukemia (AML).
SparkCures ID | 1350 |
---|---|
Trial Phase | Phase 1 |
Enrollment | 37 Patients |
Treatments |
|
Tags | |
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria:
Diagnosis of one of the following hematologic malignancies:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Please visit the ClinicalTrials.gov page for historical site information.
View Centers